Literature DB >> 15535134

Loss of heterozygosity at 6q is frequent and concurrent with 3p loss in sporadic and familial capillary hemangioblastomas.

Sebsebe Lemeta1, Lea Pylkkänen, Markku Sainio, Mika Niemelä, Sirkku Saarikoski, Kirsti Husgafvel-Pursiainen, Tom Böhling.   

Abstract

Capillary hemangioblastoma is a benign tumor, occurring sporadically or as a manifestation of von Hippel-Lindau (VHL) disease. Inactivation of the VHL gene at 3p25-26 has been demonstrated in all VHL-associated hemangioblastomas. However, the VHL gene has been found to be inactivated in only 20% to 50% of sporadic tumors. So far, no other gene has been reported to be involved in the development of hemangioblastomas. DNA losses at 6q are frequent alterations in hemangioblastomas, as shown by comparative genomic hybridization. We therefore analyzed 15 hemangioblastomas for loss of heterozygosity (LOH) on chromosome 3p and 6q to reveal the frequency of allelic losses and to determine minimal deleted areas. We detected LOH at 6q for one or more markers in 11 (73%) out of 15 cases (in 9 of 11 sporadic and in 2 of 4 VHL-associated tumors). The analyses revealed a minimal 3-megabase (Mb) deleted region at 6q23-24, where 9 of 11 (82%) informative cases showed LOH. LOH at 3p was seen in 14 out of 15 tumors. LOH occurred concurrently at 6q and 3p in 67% of cases. Our data strongly suggests that a tumor suppressor gene located at 6q23-24 is involved in tumorigenesis of hemangioblastomas, in addition to the VHL gene.

Entities:  

Mesh:

Year:  2004        PMID: 15535134     DOI: 10.1093/jnen/63.10.1072

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  7 in total

1.  Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas.

Authors:  David Taïeb; Anne Barlier; Chunzhang Yang; Morgane Pertuit; Aurélie Tchoghandjian; Claire Rochette; Hélène Zattara-Canoni; Dominique Figarella-Branger; Zhengping Zhuang; Karel Pacak; Philippe Metellus
Journal:  J Neurooncol       Date:  2015-10-29       Impact factor: 4.130

2.  Parkin gene alterations in ovarian carcinoma from northern Indian population.

Authors:  Syed Jafar Mehdi; Asgar Ali; M Moshahid Alam Rizvi
Journal:  Pathol Oncol Res       Date:  2011-01-10       Impact factor: 3.201

3.  Allelic loss of 6q25-27, the PARKIN tumor suppressor gene locus, in cervical carcinoma.

Authors:  S J Mehdi; M S Alam; S Batra; M M A Rizvi
Journal:  Med Oncol       Date:  2010-07-22       Impact factor: 3.064

4.  Differences in genetic and epigenetic alterations between von Hippel-Lindau disease-related and sporadic hemangioblastomas of the central nervous system.

Authors:  Shunsaku Takayanagi; Akitake Mukasa; Shota Tanaka; Masashi Nomura; Mayu Omata; Shunsuke Yanagisawa; Shogo Yamamoto; Koichi Ichimura; Hirofumi Nakatomi; Keisuke Ueki; Hiroyuki Aburatani; Nobuhito Saito
Journal:  Neuro Oncol       Date:  2017-09-01       Impact factor: 12.300

5.  Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene.

Authors:  Chuan Shen; Rameen Beroukhim; Steven E Schumacher; Jing Zhou; Michelle Chang; Sabina Signoretti; William G Kaelin
Journal:  Cancer Discov       Date:  2011-06-07       Impact factor: 39.397

6.  Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.

Authors:  Ganesh M Shankar; Amaro Taylor-Weiner; Nina Lelic; Robert T Jones; James C Kim; Joshua M Francis; Malak Abedalthagafi; Lawrence F Borges; Jean-Valery Coumans; William T Curry; Brian V Nahed; John H Shin; Sun Ha Paek; Sung-Hye Park; Chip Stewart; Michael S Lawrence; Kristian Cibulskis; Aaron R Thorner; Paul Van Hummelen; Anat O Stemmer-Rachamimov; Tracy T Batchelor; Scott L Carter; Mai P Hoang; Sandro Santagata; David N Louis; Fred G Barker; Matthew Meyerson; Gad Getz; Priscilla K Brastianos; Daniel P Cahill
Journal:  Acta Neuropathol Commun       Date:  2014-12-24       Impact factor: 7.801

7.  Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma.

Authors:  Roeliene C Kruizinga; Denise M S van Marion; Wilfred F A den Dunnen; Jan C de Groot; Eelco W Hoving; Sjoukje F Oosting; Hetty Timmer-Bosscha; Rosalie P H Derks; Chantal Cornelissen; Rob B van der Luijt; Thera P Links; Elisabeth G E de Vries; Annemiek M E Walenkamp
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.